Neurotrophic Keratitis: Exploring the Therapeutic Landscape

0.50 CME
0.50 CME WITH ABO Continuing Certification
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Faculty Photo


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Dompé US, Inc.

Activity Description

Neurotrophic keratitis (NK) is a degenerative disease characterized by decreased corneal sensitivity and suboptimal corneal healing. While rare, it increases with age and can lead to ulceration, infection, melting, and perforation secondary to poor healing. NK is often overlooked or diagnosed too late in the course of the disease. New therapeutic modalities hold promise in treating this vision-threatening disease. In this educational activity, expert clinicians discuss optimal practices to diagnose and treat NK.

Target Audience

The intended audience for this activity is comprehensive ophthalmologists and other health care professionals involved in the management of patients with neurotrophic keratitis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine the pathophysiology, etiology, and burden of neurotrophic keratitis including the need for early and accurate diagnosis based on evidence-based measures.
  • Evaluate the clinical evidence of current and emerging therapies in the management of neurotrophic keratitis that may reduce progression of the disease.

Activity Chair

John D. Sheppard, MD, MMSc
President, Virginia Eye Consultants
Professor of Ophthalmology, Microbiology &
Molecular Biology, Ophthalmology Residency
Research Program Director, Clinical Director
Thomas R. Lee Center for Ocular Pharmacology
Eastern Virginia Medical School
Norfolk, VA


Preeya K. Gupta, MD
Triangle Eye Consultants
Durham, NC

Edward J. Holland, MD
Director of Cornea
Cincinnati Eye Institute
Professor of Clinical Ophthalmology
University of Cincinnati
Edgewood, KY


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, July 20, 2021, to July 19, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 2 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

John D. Sheppard, MD, MMSc
Consulting Fee: Bio-Tissue, Dompé, Noveome/Stemnion
Speakers Bureau: Bio-Tissue, Dompé, Noveome/Stemnion
Ownership Interest: Noveome/Stemnion

Preeya K. Gupta, MD
Consulting Fee: Alcon, Allergan, HanAll, J&J Vision, Kala, New World Medical, Novartis, Ocular Therapeutix, Oyster Point, ReGenTree, Sight Sciences, Sun, TearLab, TissueTech, Zeiss

Edward J. Holland, MD
Consulting Fee: Abingworth, Aerie, Akros, Alcon, Aldeyra, Allegro, Allergan, Azura, BlephEx, BRIM Biotechnology, Claris, CorneaGen,  CorNeat, Dompé, Expert Opinion, EyePoint, Glaukos, Gore, HanAll, Invirsa, Kala, Mati, Merck KGaA, Novartis NIBR, Novartis Pharmaceuticals, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point, Precise Bio, Prometic, ReGenTree, Retear, Senju, Shire, Sight Sciences, SLACK Incorporated, Tarsus, TearLab, Vomaris, Zeiss
Speakers Bureau: Alcon, Novartis, Omeros, Senju, Shire
Contracted Research: Alcon, Mati, Novartis, Omeros, Senju, Shire

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at